Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous HB-adMSCs in Multiple Sclerosis
NCT05116540Phase 2Completed
- Sponsor
- Hope Biosciences
- Start
- Nov 2021
- Primary completion
- Jun 2024
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in relapsing-remitting multiple sclerosis (RRMS) comparing HB-adMSCs with Placebo (2 arms). Primary endpoints: Physical Health Composite Score - Multiple Sclerosis Quality of Life (MSQOL) 54 Instrument at Week 52, Mental Health Composite Score - Multiple Sclerosis Quality of Life (MSQOL) 54 Instrument at Week 52 and 1 more. Started Nov 2021; status: completed.
02
Drugs
allogeneic HB-adMSCs
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)
Beyond the preview
Go deeper on NCT05116540.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05116540.